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Summary Endogenously synthesised protoporphyrin IX (PpIX) following the administration of 5-amino-
laevulinic acid (ALA) is an effective photosensitiser for photodynamic therapy (PDT). Following intravenous
administration, PpIX accumulates predominantly in mucosa of hollow viscera and on light exposure, mucosal
ablation results with relative sparing of the submucosa and muscularis layers. Oral administration is effective
with ALA in contrast to conventional exogenous photosensitisers such as haematoporphyrin derivative and
phthalocyanines. Oral administration of ALA is also simpler, safer, cheaper and more acceptable to patients.
We studied the porphyrin sensitisation kinetics profile in the stomach, colon and bladder in normal rats
following enterally and parenterally administered ALA using microscopic fluorescence photometric studies of
frozen tissue sections. Mucosal cells in all three organs exhibit higher fluorescence levels as compared with
underlying smooth muscle following both intravenous and oral administration. Peak concentration were seen
4 h after sensitisation at the highest doses used (200 mg kg-' i.v., 400 mg kg-' oral), and slightly earlier with
lower doses. The temporal kinetics of both routes of administration were similar although a higher oral dose
was required to achieve the same tissue concentration of PpIX. The highest level of fluorescence was achieved
in the gastric mucosa and in decreasing levels, colonic and bladder mucosa. A similar degree of mucosal
selectivity was achieved in each organ with each route of administration but an oral dose in excess of
40 mg kg- was required to achieve measurable PpIX sensitisation. In a pilot clinical study, two patients with
inoperable rectal adenocarcinomas were given 30 mg kg- ' and one patient with sigmoid colon carcinoma was
given 60 mg kg-' ALA orally. Serial biopsies of normal and tumour areas were taken over the subsequent
24 h. Fluorescence microscopy of these specimens showed maximum accumulation of PpIX 4 to 6 h after
administration of 30 mg kg-' ALA. There was greater PpIX accumulation in tumour than adjacent normal
mucosa in two patients. Preferential PpIX accumulation in tumour was greater in the patient receiving
60 mg kg-' ALA.
Photodynamic therapy (PDT) is a promising new cancer
treatment modality. Very few tumours show intrinsic resis-
tance to PDT (Dougherty, 1990) and unlike ionising radiation
and chemotherapy, PDT is devoid of general or cumulative
toxicity. The basis of this therapy involves the in situ
photoactivation of an otherwise non toxic drug, a photosen-
sitiser, which has accumulated in tumour and normal tissues
following parenteral administration. The resultant photo-
chemical reaction gives rise to a highly active singlet oxygen
species capable of causing cell death (Weishaupt et al., 1976).
This effect is non selective and normal cells are just as
susceptible to damage as tumour cells. However, the very
short half life of this species ensures that cytotoxicity is
localised only to the site of its generation which in turn
partly correlates to the distribution of the photosensitiser.
The most widely studied photosensitiser is Photofrin which
until recently, was the only photosensitiser approved for
clinical use. Photofrin, though a potent photosensitiser, cau-
ses prolonged cutaneous photosensitivity (Razum et al., 1987)
and offers limited tumour selectivity (Agrez et al., 1983;
Gomer & Dougherty, 1979). We have recently reported on
the photosensitisation kinetics produced by systemic adminis-
tration of another agent, 5-aminolaevulinic acid (ALA)
(Bedwell et al., 1992; Loh et al., 1992). ALA is a natural
precursor of haem. The conversion of glycine and succinyl
co-enzyme A into ALA represents the first committed step in
haem biosynthesis. This step is rate limiting and tightly
regulated. The next rate limiting step down the biosynthetic
chain occurs at the conversion ofphotoactive protoporphyrin
IX (PpIX) to non photoactive haem. Following intravenous
administration of exogenous ALA, the natural regulatory
mechanisms become overloaded and porphyrin intermediates
accumulate. HPLC analysis of porphyrins extracted chemi-
cally from tissue specimens of animals given ALA intra-
venously has demonstrated PpIX to be the predominant
porphyrin species accumulated in tissue with a very small
contribution from coproporphyrin (<4%) at 30 min follow-
ing administration (Loh et al., in press). Because different
tissues have different requirements for haem, an important
component in vital respiratory pigments, the pattern of PpIX
accumulation reflects this difference. Following intravenous
administration, ALA leads to a rapid and even build up of
PpIX in the mucosa of hollow viscera while the underlying
muscularis layer is sensitised to a much lesser extent (Loh et
al., 1992). The photosensitisation produced is short lived
lasting less than 24 h and consequently prolonged skin
photosensitivity is not a problem (Divaris et al., 1990;
Bedwell et al., 1992; Loh et al., 1992). We have also demon-
strated photodynamic effects on a rat colon tumour after
intravenous ALA (Bedwell et al., 1992). Preliminary clinical
studies (Kennedy et al., 1990) have shown that ALA is taken
up well by skin tumours when applied topically although the
depth of penetration appears to correlate with the duration
of incubation (Szeimies et al., 1992).
ALA is supplied as a hydrochloride salt and is acidic in
solution. Intravenous administration in animals ofunbuffered
solution is not only associated with pain (Loh, unpublished
observation) but also causes bradycardia and hypotension
whereas buffered ALA solution does not cause these effects
(Edwards et al., 1984). However, ALA solution buffered to a
pH of 7.4 is chemically unstable (Bedwell, unpublished obser-
vation) and should be used immediately after it is made up.
This makes preparation inconvenient and liable to incon-
sistency. Oral administration is simple, does not require full
buffering and can be undertaken by patients themselves prior
to therapy without supervision. As ALA is analogous to
amino acids, rapid absorption can be expected following
ingestion. However, little is known with regard to the
photosensitisation kinetics after oral administration apart
from reports of mild cutaneous photosensitivity in human
volunteers after oral ingestion (Berlin et al., 1956). For oral
Correspondence: Dr C.S. Loh, National Medical Laser Centre,
Faculty of Clinical Sciences, University College London, The Rayne
Institute, 5 University Street, London WC1E6JJ, UK.
Received 1 December 1992; and in revised form 22 February 1993.
Br. J. Cancer (I993), 68, 41 51 '." Macmillan Press Ltd., 199342 C.S. LOH et al.
delivery of ALA to be useful clinically, it should be reliably
absorbed following ingestion and undergo minimal pre-
systemic metabolism. It has recently been shown that a high
serum ALA level can be achieved in human volunteer by
continuous enteral infusion of ALA solution (Mustajoki et
al., 1992). The aim of this study is to explore the suitability
of ALA administration via the enteral route for photosen-
sitisation of tissue structures both in and distant from the
alimentary tract by studying the kinetics of PpIX fluore-
scence produced in these organs.
Materials and methods
Young female adult Wistar rats approximately 200 g in
weight were used for this study. ALA was obtained in a 98%
pure powder (formula weight 167.6) from Sigma Chemicals
Limited (Poole, UK). For intravenous administration, it was
dissolved in physiological strength phosphate buffered saline
(pH = 2.8).
ALA induced porphyrin fluorescence was characterised by
means ofemission fluorescence spectroscopy. Using a Perkin-
Elmer LS-5B spectrofluorimeter (slits at 5 nm resolution), an
emission spectrum was obtained (excitation at 400 nm) from
an ex vivo whole tissue specimen of rat stomach 4 h after
intravenous administration of 200 mgkg-' of ALA.
For the study of PpIX induced porphyrin kinetics follow-
ing enteral and parenteral administration, animals were
divided into two groups. Animals in the parenteral group
were given 200 mgkg-' ALA intravenously into the tail vein
after intramuscular anaesthesia (fentanyl and fluanisone). In
the comparative enteral group, each animal received 400 mg
kg-' of ALA dissolved in 1 ml of phosphate buffered saline
(pH = 2.8) and administered by gastric gavage. A long bulb
tip needle was introduced orally down the oesophagus into
the stomach, the ALA solution injected into the stomach and
the needle withdrawn. As rats are incapable of vomiting or
regurgitation, all animals ingested the full delivered dose.
Because of likely first-pass metabolism, a higher dose was
employed for oral administration. Animals were then killed
1, 2, 4, 6, 8 and 24 h after administration for study. A disc of
glandular stomach, a short segment of proximal colon and
the entire bladder were excised, washed free of luminal con-
tent and immediately frozen in a bath ofisopentane cooled in
liquid nitrogen. Frozen specimens were mounted on OCT
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medium (tissue tek II embedding compound, BDH) and
10lm thick unstained sections were cut using a Cryocut E
microtome (Reichert-Jung) for study. Two further groups of
animals received lower doses (40mgkg-' and 200mgkg-')
enterally for evaluation of first pass metabolism of ALA.
Gastric and colonic specimens were retrieved as described
above at 1, 2, 4 and 6 h following administration and pro-
cessed for study as outlined above. In addition to the rat
experiments, pilot clinical studies were also undertaken. Per-
mission was granted by the Department of Health to give
ALA orally to patients with colo-rectal cancer (Doctors and
Dentists exemption certificate). The drug was prepared by
pharmacy in University College Hospital and the project
approved by the hospital's Research Ethics Committee.
Three male patients (aged 84, 79 and 89 years) with his-
tologically proven and inoperable colo-rectal adenocarcin-
oma (8, 16 and 20 cm from anal verge respectively) gave their
informed consent to participate in this study. The first two
patients (WL & EB) were given a solution of ALA mixed
with fruit juice at a dose of 30mgkg'. This dose was
chosen as previous human volunteers had ingested a similar
dose without any reported side effects apart from transient
skin photosensitivity (Berlin et al., 1956). After the safety of
ingesting 30mgkg'1 of ALA was established in these two
patients, the third patient (MS) was then given a similar
solution at a dose of 60mgkg-'. The solution was drunk
immediately following preparation to avoid ALA degrada-
tion which may proceed rapidly at neutral pH but is inhibited
under the acidic conditions in the stomach. All three patients
were kept from bright light for 24 h following ingestion.
Venous blood was withdrawn from peripheral veins immed-
iately prior to and at 24 and 72 h following ALA ingestion
for assay of serum urea, creatinine, sodium, potassium, total
bilirubin, alkaline phosphatase, aspartate transaminase, albu-
min and creatinine kinase as well as for a blood count.
Biopsy specimens were taken during fibreoptic endoscopy
before ingestion as well as at 2, 4, 5, 6, 7 and 8 h after
ingestion from the tumour and adjacent normal rectal mu-
cosa and prepared as above for microscopic fluorimetry. No
speciment was obtained at 8 h in the third patient (MS).
Microscopic fluorescence photometry of the frozen tissue
sections was carried out on an inverted phase contrast micro-
scope on which was mounted a sensitive slow scan charge
coupled device (CCD) camera. The set up of this equipment
has been described in detail in previous papers (Chan et al.,
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Figure 1 Emission spectrum from a piece of stomach excised 4 h after intravenous administration of 200 mgkg-' ALA (peak
emission wavelength = 635 nm). Excitation wavelength used was 400 nm.ORAL VS I.V. ALA FOR PDT 43
1989, Bedwell et al., 1992). Briefly, PpIX fluorescence was
excited by means of an 8 mW helium neon laser (632.8 nm)
which was chosen because of its spectral purity, low cost and
more importantly, the relatively low tissue autofluorescence
produced using this wavelength in contrast to shorter wave-
length excitation. Fluorescence detection ranged from 660-
710 nm. All photometry was carried out under the same
magnification (10 x objective, N.A. 0.3). The fluorescence
signal was processed by a personal computer into a falsely
colour coded or grey scale fluorescence image of the section.
The software also enabled quantitative measurement of
fluorescence levels over selected areas of interest on the dis-
played fluorescence image. Representative areas of mucosa,
submucosa and muscularis propria were selected for
fluorescence measurements which were then corrected for
autofluorescence levels of each respective tissue layer as
measured on specimens from control unsensitised animals.
These corrected fluorescence measurements had been shown
to correlate well with the total quantity of chemically ex-
tracted PpIX from tissue specimens of animals given ALA
(Loh et al., in press). Following fluorescence microscopy, the
specimens were fixed in formalin and stained with haema-
toxylin and eosin for comparative light microscopy. The
fluorescence image and its comparative light micrograph were
photographed for documentation.
Results
The fluorescence emission spectrum of a piece of stomach
(whole tissue) after intravenous ALA (200 mg kg-1) as shown
a
b
Figure 2 a, Grey scale fluorescence image of a frozen section of bladder wall 4 h after intravenous administration of 200 mg kg-1
of ALA. The upper bar represents the fluorescence scale; white = high intensity, black = low intensity). The mucosal layer is
brightly fluorescent while fluorescence levels in all the other layers of the bladder wall are much lower. Scale: the bar in the right
bottom corner represents 100 lim. (muc = mucosa; lp = lamina propria; mus = smooth muscle). b, Fluorescence profile of the
boxed area in a, as displayed in a three dimensional contour graph.44 C.S. LOH et al.
in Figure 1 is in good agreement with porphyrin fluorescence
emission spectra from normal colon strips taken from ani-
mals injected with 200mgkg' of ALA (Bedwell et al.,
1992). HPLC analysis ofextracted porphyrin content (Loh et
al., in press) has recently demonstrated that after intravenous
administration of 200 mgkg-' ALA to rats, more than 95%
of the porphyrin present is protoporphyrin IX in normal
colon, stomach and tumour and it is reasonable to assume
the same applies to oral administration. On increasing the
ALA dose from 200mgkg-' to 1.6 g kg-', no change in
spectral profile was observed which suggests that porphyrin
aggregation which can produce a red-shift (approximately
10nm) in the emission spectrum (Reddi & Jori, 1988) may
not occur to a significant extent. Time-resolved measure-
ments however might provide more definitive conclusions
and would also help to quantify the influence of fluorescence
quenching.
Figure 2 (a and b) shows a typical microscopic fluor-
escence image ofa frozen section of rat bladder as well as the
quantitative fluorescence profile across the full thickness of
the bladder wall. Fluorescence levels in the mucosa, sub-
mucosa and muscularis propria are displayed in Figures 3a
and b (stomach), Figure 4a and b (colon), Figure 5a and b
(bladder). Highest fluorescence levels were seen in the mu-
cosae of all three organs studied. Following oral administra-
tion, mucosal fluorescence levels rose to a peak 4h after
administration in all three organs and declined rapidly
thereafter reaching background levels by 24 h (Figures 3a, 4a
a
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Figure 3 Mean fluorescence levels (± s.d.) in the mucosa, submucosa and muscularis propria ofthe stomach at various times after
ALA administration (a = 200 mgkg-' intravenously; b, = 400 mgkg-' by gastric gavage). Each value represents the mean of 6
measurements obtained from three animals. a, is reproduced from Loh et al., 1992.ORAL VS I.V. ALA FOR PDT 45
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Figure 4 Mean fluorescence levels ( ± s.d.) in the mucosa, submucosa and muscularis propria of the colon at various times after
ALA administration (a = 200 mg kg-' intravenously; b = 400 mg kg-' by gastric gavage). Each value represents the mean of six
measurements obtained from three animals. a, is reproduced from Bedwell et al., 1992.
and 5a). With intravenous administration, peak fluorescence
was achieved at 3 h after injection in gastric and vesical
mucosa and 4 h in the colon. Although comparable levels of
fluorescence build up occurred in the smooth muscle layers of
all three organs, the gastric mucosa exhibited the highest
peak fluorescence level followed by the colonic and then
vesical mucosa with both routes of administration. Conse-
quently, different levels of mucosa to muscle differential as
represented by the fluorescence ratios between mucosa and
muscularis (Figure 6) were achieved. Fluorescence levels in
the gastric and colonic mucosa following different doses of
ALA administered enterally are shown in Figures 7 and 8
respectively. Fluorescence levels achieved with 400 mg kg-'
are higher than those achieved with 200 mg kg-' at all times
while fluorescence levels measured after an oral dose of
40 mg kg-' barely exceed background levels in both organs.
No side effect was encountered following ALA ingestion in
all three patients. In two patients (WL & MS), there was an
increase of aspartate transaminase level from 24 to 84 u 1-'
and 22 to 150ul-1 respectively (normal range 11-55ul-')
24 h after administration. Plasmal total bilirubin level in the
first patient (WL) also increased from 9 to 20 gmol V' (nor-
mal range <17 pmolI`) over the same period. By 72 h,
these levels has all returned to normal. Fluorescence mea-
surement of the biopsy materials from them were represented
in Figure 9. Peak fluorescence was achieved between 4 and
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Figure 5 Mean fluorescence levels ( ± s.d.) in the mucosa, lamina propria and muscularis propria of the bladder at various times
after ALA administration (a = 200 mg kg-' intravenously; b = 400 mg kg- ' by gastric gavage). Each value represents the mean of 6
measurements obtained from three animals.
6 h following ingestion of 30 mg kg-' of ALA although
enhanced PpIX accumulation in the tumour was only seen in
one patient (EB) between 5 and 7 h following ingestion.
Rather different temporal kinetics were seen when 60 mg
kg-' of ALA was given. Fluorescence level in normal tissue
had already reached a peak at 6 h after administration while
that in tumour was still rising. Figure 10 represents a grey
scale microscopic fluorescence image of a tumour section
from this patient 4 h after ingestion of ALA and shows high
levels ofPpIX fluorescence in the cytosol ofepithelial tumour
cells.
Discussion
The mertis of using quantitative microscopic fluorimetry for
the study of photosensitiser distributions have been discussed
in previous papers (Barr et al., 1988; Pope et al., 1991;
Bedwell et al., 1992). We have chosen to use 632.8 nm excita-
tion instead of exciting the porphyrin Soret band near
400 nm in order to keep tissue autofluorescence to a low level
and although tissue porphyrin fluorescence is correspondingly
lower, signal levels are still well within the detection range of
the highly sensitive CCD camera. Emission spectroscopy of
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Figure 6 Ratio of mean fluorescence levels in mucosa and muscularis propria of the stomach, colon and bladder at various times
following either 200mg kg-' of ALA administered intravenously or 400mgkg-' ALA administered by gastric gavage.
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Figure 7 Mean fluorescence levels ( s.d.) in the gastric mucosa at various times after oral administration of ALA at doses of
40 mgkg-', 200 mgkg-' and 400 mg kg . Each value represents the mean of six measurements obtained from three animals.
ex vivo tissue specimens and HPLC analysis of chemically
extracted porphyrins from animal tissue following ALA
administration (Loh et al., in press) indicate that PpIX is the
predominant porphyrin produced after ALA administration.
We have recently shown satisfactory correlation of ALA
induced tissue fluorescence measurements using this set up
with extracted PpIX levels (Loh et al., in press) as well as
with subsequent biological effects upon light exposure in
earlier studies on normal rat colon and stomach (Bedwell et
al., 1992; Loh et al., 1992) and moreover, the combination of
microscopy and fluorimetry enables us to quantitatively map
out the porphyrin fluorescence at a microscopic level, and
consequently, the photodynamic effect can be predicted down
to a microscopic level.
Following intravenous or oral administration, a rapid
build up of PpIX fluorescence occurred over the first few
hours followed by an almost equally rapid decline. By 24 h,
fluorescence had returned to background level. Our previous48 C.S. LOH et al.
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Figure 8 Mean fluorescence levels ( s.d.) in the colonic mucosa at various times after oral administration of ALA at doses of
40 mgkg-', 200 mgkg-' and 400 mg kg-'. Each value represents the mean of six measurements obtained from three animals.
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Figure 9 Mean fluorescence levels in the colonic tumours and adjacent normal rectal mucosa of three patients (EB, WL & MS) at
various times after oral administration of 30 mg kg-' (EB & WL) and 60 mg kg-'I (MS) of ALA. Each value represents the mean
of three measurements.
results showed that peak levels of fluorescence were achieved
earlier with lower doses of ALA after intravenous admini-
stration (Loh et al., 1992) and the present results show the
same is true for oral administration. At the highest doses
used (200 mg kg-' intravenously and 400 mg kg-' orally),
the peak occurred 4 h after administration. These results
show that the temporal kinetics of photosensitisation with
ALA are very much more favourable than with HpD.
The bioavailability of a drug following oral ingestion is
usually less than that following intravenous administration due
to presystemic drug elimination. First-pass metabolism can
occur in the intestinal lumen by the resident flora (Renwick,
1982), within the wall of the gastrointestinal tract (Caldwell
& Marsh, 1982) and in the liver (George & Shand, 1982).
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Figure 10 Grey scale fluorescence micrograph of a section of human rectal adenocarcinoma 4 h after oral administration of
30 mgkg-' ALA. Bright areas depict high fluorescence levels. (n = nucleus, c =cytoplasm). Scale: the bar on the right represents
25pgm.
The usefulness of the oral route of administration for ALA
will depend on the efficiency of its absorption and the extent
of these various forms offirst-pass metabolism. Special trans-
port mechanisms exist for amino acids (Van Dyke, 1989) and
although little is known about the mechanism of ALA
absorption from the alimentary tract, it can be expected to
undergo similar absorption processes. Following ingestion,
ALA needs to pass through intestinal enterocytes before
entering the portal and finally systemic circulation. While the
extent of ALA metabolism by the normal gut flora is largely
unknown, the gastrointestinal mucosal cells have been shown
to possess a large capacity of PpIX biosynthesis after intra-
venous administration (Bedwell et al., 1992; Loh et al., 1992).
In addition, the liver has by far the largest capacity for haem
synthesis outside the haemopoietic system (Sardesai et al.,
1964). A degree of first pass metabolism of the absorbed
ALA can be expected within the mucosal cells to produce
porphyrins and haem. In the liver, the extent of first pass
metabolism of ALA depends on portal blood flow and the
metabolic activity of hepatic enzymes (Genecin et al., 1991).
In the presence of portal hypertension for example, con-
siderable portal systemic shunting can occur (Arroyo et al.,
1991) which will affect the extent of hepatic first pass
metabolism. In a normal liver, there is maximal enzymatic
activity and minimal portal systemic shunting and hepatic
first pass metabolism is likely to be considerable. A very high
extent of hepatic first pass metabolism of a drug will greatly
reduce its systemic bioavailability. In the case of ALA, while
any fluorescence build up in the gastrointestinal mucosa may
represent local absorption, good systemic bioavailability of
ALA following oral ingestion is indicated by fluorescence
build up in organs outside the gastrointestinal tract. In this
study, we have chosen to evaluate the bladder, an organ in
which PDT has considerable clinical potential (Pope et al.,
1991).
In the first part of this study, we have shown that in all
three organs investigated, the temporal fluorescence kinetics
after oral administration were comparable with that after
intravenous injection, indicating rapid and reliable absorp-
tion of ALA following ingestion. However, as a result of
presystemic metabolism, the absolute tissue concentrations of
PpIX produced by 400 mg kg-' of ALA administered enter-
ally were only comparable to those produced by 200 mg kg-'
of ALA administered parenterally in all three tissue types.
Good systemic bioavailability for photosensitisation after
oral administration was demonstrated by the build up of
PpIX fluorescence in the bladder. Photosensitisation of the
bladder mucosa can come from blood borne ALA or from
direct absorption of excreted urinary ALA. Any significant
urinary ALA excretion requires a good serum ALA level and
would be a further indication of systemic bioavailability
although we have not investigated this aspect.
It is also apparent that for a given dose of ALA, the level
of PpIX fluorescence build up differs from one epithelial
tissue to another, irrespective of the route of administration.
Thus, the gastric mucosa shows the highest level of PpIX
accumulation followed by colonic and then vesical mucosa.
This difference in PpIX biosynthesis capacity between differ-
ent epithelial tissue is likely to correlate with the differential
requirement of these tissues for haem, an important compo-
nent in the vital respiratory'pigments, and probably reflects
their different metabolic rates. Gastric mucosa, consists of
actively secretory epithelial cells and can be expected to have
a higher metabolic demand than for the bladder mucosa, a
non secretory epithelium. We have shown that a rat colon
tumour has higher PpIX synthetic capacity in the presence of
exogenous ALA as compared with normal colonic mucosa,
probably due to a higher level of cell metabolism (Bedwell et
al., 1992). It will be interesting to see if adenocarcinomas
with varying degrees of differentation and thus secretory
function as well as growth rate exhibit similar variation
although no data on this is yet available. In the normal
organs, the different extent of PpIX accumulation in the
main tissue layers gives rise to different degrees of mucosal
selectivity. The extent of this differential at the time of light
exposure will determine the degree of selectivity of the subse-
quent tissue necrosis that can be achieved. Although highest
levels of mucosal selectivity were achieved 1 h following50 C.S. LOH et al.
administration of ALA (Figure 6), tissue fluorescence levels
only reach their maxima between 2 and 4 h after administra-
tion (Figures 3a and b, 4a and b and 5a and b). Unless a
reliable quantity of PpIX can be accumulated by 1 h, light
exposure would be better carried out at the time of peak
fluorescence to ensure consistent tissue effect. Over this
period, mucosal fluorescence was approximately ten times
that of muscularis in the stomach, seven times in the colon
and five times in the bladder (Figure 6). These ratios are
higher than the best tumour: normal ratio of conventional
photosensitisers such as HpD or phthalocyanine (Agrez et
al., 1983; Gomer & Dougherty, 1979; Tralau et al., 1987). It
is worth emphasising that the ratios between neoplastic
mucosa and underlying muscle are likely to be even higher in
these organs as already demonstrated in the colon (Bedwell
et al., 1992). However, a mucosa to muscle ratio of 5 in the
bladder is marginally better than that attained in the bladder
using intravenous aluminium sulphonated phthalocyanine
when a ratio of between 3 and 4 was achieved (Pope et al.,
1991). Pope et al. were able to exploit this relatively small
ratio with phthalocyanine photosensitisation at a dose of
0.5 mg kg' to destroy bladder mucosa while not damaging
muscle and so preserving bladder function (Pope et al., 1991).
At this dose, the concentration in the mucosa was above the
threshold for PDT damage whereas that in the muscle was
below the threshold. We would antipicate that similar selec-
tive necrosis of vesical mucosa (as required for safe treatment
of carcinoma in situ ) would be possible in the bladder using
ALA given orally or intravenously.
In the second part of this study, we have demonstrated
that an oral dose of 40 mg kg-' of ALA led to only a very
small fluorescence level and even in the gastric mucosa, this
level was lower than that attained with 20 mg kg' given
intravenously (Loh et al., 1992). It would appear that an oral
dose in excess of 40 mg kg' is required to achieve reliable
systemic bioavailability of ALA for induction of photosen-
sitisation in normal rat tissue. However, it is important to
bear in mind that the degradation (by ferrochelatase) of
PpIX synthesised at very low bioavailability of ALA is prob-
ably no longer rate limiting, as in the situation found in
normal tissue in the absence of exogenously supplied ALA,
and consequently PpIX accumulation does not occur. There
is evidence to show that ferrochelatase activity in some
tumour tissues is reduced (Dailey & Smith, 1984; Schoenfeld
et al., 1988; El-Sharabasy et al., 1992) and therefore, accumu-
lation of PpIX in tumour tissue may occur even at such low
oral dose. If this can be achieved, truly tumour selective
photodynamic effects may yet be possible.
We can estimate peak mucosal levels found in this work to
be about 10 pg g'l (Loh et al., in press) which we know (Loh
et al., 1992) are more than sufficient to produce full thickness
necrosis of normal stomach using 50 J at 630 nm. Fluor-
escence profiles in both normal and tumour tissue in the
three human volunteers confirmed that systemically admini-
stered ALA can produce levels of PpIX fluorescence which
on the basis these animal studies (Loh et al., 1992) should be
sufficient for PDT. It is noteworthy that good fluorescence
levels were achieved with an oral dose of 30 mg kg-' while
an oral dose of 40 mg kg-' did not lead to any significant
fluorescence build up in rat colonic mucosa. This is because
the metabolic rate is higher in smaller animals. In addition,
cross species difference in porphyrin biosynthesis kinetics
cannot be ruled out. Thus our results are in keeping with the
observation of cutaneous photosensitivity reported in human
volunteers ingesting doses not greater than 35 mg kg' of
ALA (Berlin et al., 1956). The quantitative and temporal
kinetic profiles of the tumours in the two volunteers receiving
30 mg kg-' ALA appeared to differ markedly. Enhanced
fluorescence accumulation in tumour as compared to adja-
cent normal mucosa was seen in two patients (EB, 30mg
kg-' & MS, 60 mg kg-'). This preferential accumulation was
especially marked in the latter patient receiving 60 mg kg-'
ALA. Unfortunately, no 8 h datum was available in this
patient and peak tumour fluorescence may have not been
reached at 7 h after administration.
As shown in Figure 10, there appeared to be some varia-
tion in the levels of fluorescence in different parts within the
same tumour. There are several possible explanations for this
observation. The level of accummulated PpIX is a function
of both the initial substrate (ALA) concentration and the
profile of the enzymes responsible for PpIX biosynthesis.
Intracellular ALA levels achieved may vary from cells to cells
depending on blood supply as exogenous ALA is delivered
through the blood stream. Furthermore, if ALA uptake is an
energy dependent process, anoxia may further affect this
uptake. Finally, the expression of genes responsible for PpIX
biosynthesis can be expected to vary from cell to cell within
the same tumour as they go through different phases of their
cell cycles. The consequence is an uneven photosensitisation
of tumour cells with the risk of incomplete treatment. How-
ever, this apparent limitation may be overcome by various
means. We had earlier shown that even stable smooth muscle
cells can accumulate enough PpIX for PDT given the right
ALA dose (Loh et al., 1992). The risk of incomplete tumour
photosensitisation may be obviated by using a higher ALA
dose but this may be at the expense of loosing tumour
selectivity as underlying normal tissue structures such as
muscle also become sensitised. Alternatively, continuous
ALA administration over a period of time may help to
reduce the effect of cell cycle asynchrony of the tumour cells
within the same tumour. As long as the rate of PpIX syn-
thesis over that period of time exceeds the rate of PpIX
elimination, PpIX accumulation can still be expected to
occur. Such an approach has recently been used to selectively
induce PpIX sensitisation of liver metastases (van Hillegers-
berg et al., 1992). Finally, combination of the direct cellular
effect by ALA with an exogenous vascular photosensitiser
may be considered. However, unless the exogenous photosen-
sitiser used has similar photochemical characteristics as
PpIX, such an approach would be complicated as it would
involve excitation at two different wavelengths. Furthermore,
the advantageous temporal kinetics of ALA induced photo-
sensitisation will also be overriden by the kinetics of the
exogenous photosensitiser used.
In conclusion, ALA administered orally produces similar
temporal fluorescence kinetics as that from intravenous ad-
ministration. Due to first-pass metabolism, a higher oral dose
of ALA is required to achieve the same level of photosen-
sitisation as intravenous administration and a dose in excess
of 40 mg kg-' is required to produce consistent photosen-
sitisation in normal mucosa in rats. Mucosal selectivity is
comparable between the two routes of administration. Oral
ALA at a dose of 30 mg kg-' appears to lead to PpIX
accumulation in normal human colonic mucosa and adeno-
carcinoma. ALA is unique as being the only agent for PDT
reported thus far which can produce reliable photosensitisa-
tion when administered orally. Further evaluation of photo-
sensitisation kinetics and preliminary clinical studies of PDT
using orally administered ALA are under way.
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